4+ hour, 21+ min ago   (113+ words) REGN7041 targets CD3, a component of the T-cell receptor complex, and was being developed as an immunomodulatory approach to non-infectious uveitis, a group of inflammatory eye diseases that can cause vision loss. Regeneron listed the candidate in Phase I development for uveitis…...

3+ hour, 7+ min ago   (143+ words) Most clinical-stage adoptive cell therapy strategies for solid tumors center on cytotoxic effector populations, including engineered CAR-T cells and tumor-infiltrating lymphocytes (TILs). CRG-150 instead uses gene-edited Tregs as the therapeutic cell population, and no other publicly disclosed clinical oncology program…...

6+ hour, 9+ min ago   (432+ words) By Mike May, PhD Credit: Image generated with Google Gemini Speaking to GEN, experts from VIVEbiotech, Terumo Blood and Cell Technologies, and Bracco describe an industry transitioning from demonstrating scientific feasibility to building robust manufacturing systems capable of delivering life-changing…...

6+ hour, 10+ min ago   (588+ words) By Gareth John Macdonald Inefficiencies that limit the global supply of viral vectors are negatively impacting the gene therapy industry, according to researchers, who say there is an urgent need for better downstream purification materials. The call came from Stefano…...

6+ hour, 5+ min ago   (341+ words) marketscreener.com 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays…...

7+ hour, 51+ min ago   (176+ words) Genome-wide CRISPR-Cas9 screens identified hundreds of genes that support or restrict cGAS–STING-induced type I interferon expression in human monocytic cells. The resulting map links interferon regulation to autophagy, RNA metabolism, and chromatin modification, and implicates TBL1XR1 and HDAC3 in promoting TBK1-mediated…...

9+ hour, 35+ min ago   (136+ words) Three months before a young boy died in Huidagene’s gene editing trial last year, the company’s former CEO Alvin Luk presented its early data at the American Society for Gene and Cell Therapy’s Presidential Symposium, one of the field’s biggest…...

9+ hour, 36+ min ago   (562+ words) Here, Stefan Braam, Chief Technical Officer at Cellistic, discusses the evolution of allogeneic cell therapy, the bottlenecks that still limit iPSC manufacturing, and what it will take to make these therapies scalable, reproducible, and accessible. How has the allogeneic cell…...

1+ day, 12+ hour ago   (84+ words) NC State University I spent my summer in Nagoya, Japan, conducting research at Nagoya University in Dr. Kenji Ichiyanagi’s Laboratory of Genome and Epigenome Dynamics under the guidance of Torahiko Yamanaka. My research focused on the epigenetic regulation of meiotic…...

13+ hour, 26+ min ago   (1109+ words) Guest Column | August 19, 2026 A conversation between Elizabeth White of the Orphan Therapeutics Accelerator and Life Science Connect's Jon O'Connell No advanced therapy developer feels good about abandoning a clinical-phase orphan drug candidate that they know has a real chance at…...